Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Entrada Therapeutics (TRDA) Enterprise Value (2022 - 2025)

Entrada Therapeutics has reported Enterprise Value over the past 4 years, most recently at -$91.1 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$91.1 million for Q4 2025, up 10.04% from a year ago — trailing twelve months through Dec 2025 was -$91.1 million (up 10.04% YoY), and the annual figure for FY2025 was -$91.1 million, up 10.04%.
  • Enterprise Value for Q4 2025 was -$91.1 million at Entrada Therapeutics, up from -$93.3 million in the prior quarter.
  • Over the last five years, Enterprise Value for TRDA hit a ceiling of -$45.2 million in Q4 2022 and a floor of -$263.9 million in Q1 2022.
  • Median Enterprise Value over the past 4 years was -$85.4 million (2023), compared with a mean of -$122.1 million.
  • Biggest five-year swings in Enterprise Value: skyrocketed 75.93% in 2023 and later tumbled 132.31% in 2024.
  • Entrada Therapeutics' Enterprise Value stood at -$45.2 million in 2022, then tumbled by 49.7% to -$67.6 million in 2023, then tumbled by 49.72% to -$101.2 million in 2024, then increased by 10.04% to -$91.1 million in 2025.
  • The last three reported values for Enterprise Value were -$91.1 million (Q4 2025), -$93.3 million (Q3 2025), and -$72.5 million (Q2 2025) per Business Quant data.